The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,022
Cho, H., Kang, H., Lee, H., & Kim, C. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071517 · Cited by 101
O’Shaughnessy, M. J., Murray, K. S., Rosa, S. P. L., Budhu, S., Merghoub, T., Somma, A. J., Monette, S., Kim, K., Corradi, R. B., Scherz, A. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0186 · Cited by 100
Kehl, K. L., Yang, S., Awad, M. M., Palmer, N., Kohane, I. S., & Schrag, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02321-z · Cited by 100
Ornstein, M. C., Pal, S. K., Wood, L. S., Tomer, J. M., Hobbs, B. P., Jia, X. S., Allman, K. D., Martin, A. M., Olencki, T. E., Davis, N. B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30513-3 · Cited by 100
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
McNamara, M. G., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102084 · Cited by 102
Kim, D. K., Jeong, J., Lee, D. S., Hyeon, D. Y., Park, G. W., Jeon, S., Lee, K. B., Jang, J., Hwang, D., Kim, H. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33991-6 · Cited by 102
Triple-Negative Breast Cancer: Current Practice and Future Directions
Costa, R. L. B., & Gradishar, W. J. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.023333 · Cited by 100
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 100
Chicas-Sett, R., Morales-Orue, I., Rodríguez‐Abreu, D., & Lara, P. C. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2017.12.004 · Cited by 102
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Frélaut, M., du Rusquec, P., Moura, A. D., Tourneau, C. L., & Borcoman, É. (2020) · BioDrugs · doi:10.1007/s40259-020-00425-y · Cited by 104
Gul, A., Stewart, T. F., Mantia, C. M., Shah, N. J., Gatof, E. S., Long, Y., Allman, K. D., Ornstein, M. C., Hammers, H. J., McDermott, D. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03315 · Cited by 100
Self-citationChoueiri, T. K., McDermott, D. F., Merchan, J. R., Bauer, T. M., Figlin, R. A., Heath, E. I., Michaelson, M. D., Arrowsmith, E. R., D'souza, A., Song, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00097-9 · Cited by 99
Self-citationThe development of immunotherapy in older adults: New treatments, new toxicities?
Hélissey, C., Vicier, C., & Champiat, S. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.05.007 · Cited by 99
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 98
Carretero-González, A., Lora, D., Ghanem, I., Zugazagoitia, J., Castellano, D., Sepúlveda-Sánchez, J. M., Lopez-Martin, J. A., Paz-Ares, L. G., & de Velasco, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24283 · Cited by 103
Self-citationImmunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 106
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
Inaguma, S., Wang, Z., Lasota, J. P., Sarlomo‐Rikala, M., McCue, P. A., Ikeda, H., & Miettinen, M. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000653 · Cited by 98
Immune checkpoint inhibitors in renal cell carcinoma
Ross, K., & Jones, R. J. (2017) · Clinical Science · doi:10.1042/cs20160894 · Cited by 100
Zhou, Q.-H., Li, K.-W., Chen, X., He, H.-X., Peng, S.-M., Peng, S.-R., Wang, Q., Li, Z.-A., Tao, Y.-R., Cai, W.-L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000157 · Cited by 97
CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
Beckermann, K. E., Hongo, R. A., Ye, X., Young, K. L., Carbonell, K., Contreras, D. C., Siska, P. J., Barone, S. M., Roe, C. E., Smith, C. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138729 · Cited by 103
Rebuzzi, S. E., Signori, A., Banna, G. L., Maruzzo, M., Giorgi, U. D., Pedrazzoli, P., Sbrana, A., Zucali, P. A., Masini, C., Naglieri, E., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211019642 · Cited by 97
Self-citationSchoenfeld, A. J., Antonia, S. J., Awad, M. M., Felip, E., Gainor, J. F., Gettinger, S. N., Hodi, F. S., Johnson, M. L., Leighl, N. B., Lovly, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2151 · Cited by 98
Wu, Z., Chen, Q., Qu, L., Li, M., Wang, L., Mir, M. C., Carbonara, U., Pandolfo, S. D., Black, P. C., Paul, A. K. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.01.028 · Cited by 99
Aging, immune senescence, and immunotherapy: a comprehensive review
Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96
Bilen, M. A., Dutcher, G., Liu, Y., Ravindranathan, D., Kissick, H. T., Carthon, B. C., Küçük, Ö., Harris, W. B., & Master, V. A. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.12.015 · Cited by 96
Adam, J., Louvet, E., Sourisseau, T., Dorvault, N., Bernard, M., Maingot, E., Faivre, L., Kuo, M.-S., Boissier, É., Dessoliers, M.-C., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000257 · Cited by 96
Does patient age influence anti-cancer immunity?
Pawelec, G. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0697-6 · Cited by 97
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sasaki, S., Nishikawa, J., Sakai, K., Iizasa, H., Yoshiyama, H., Yanagihara, M., Shuto, T., Shimokuri, K., Kanda, T., Suehiro, Y., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0880-4 · Cited by 96
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
Ricciuti, B., Leonardi, G. C., Puccetti, P., Fallarino, F., Bianconi, V., Sahebkar, A., Baglivo, S., Chiari, R., & Pirro, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.004 · Cited by 97
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 87
Kristensen, L. K., Fröhlich, C., Christensen, C. L., Melander, M. C., Poulsen, T. T., Galler, G. R., Lantto, J., Horak, I. D., Kragh, M., Nielsen, C. H., et al. (2019) · Theranostics · doi:10.7150/thno.37513 · Cited by 98
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
Powles, T. B., Walker, J., Williams, J. A., & Joaquim Bellmunt, B. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101925 · Cited by 96
Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020
Gupta, S., Cortazar, F. B., Riella, L. V., & Leaf, D. E. (2020) · Kidney360 · doi:10.34067/kid.0000852019 · Cited by 97
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Hirsch, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Drugs · doi:10.1007/s40265-020-01327-7 · Cited by 97
Self-citationDugage, M. R., Nassif, E. F., Italiano, A., & Bahleda, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775761 · Cited by 100
Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95
Zhang, T., Xie, J., Arai, S., Wang, L., Shi, X., Shi, N., Ma, F., Chen, S., Huang, L. J., Yang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12230 · Cited by 97
Jeyakumar, G., Kim, S., Bumma, N., Landry, C., Silski, C., Suisham, S., Dickow, B., Heath, E. I., Fontana, J. A., & Vaishampayan, U. N. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0287-5 · Cited by 95
Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
Tucci, M., Passarelli, A. M., Mannavola, F., Stucci, L. S., Ascierto, P. A., Capone, M., Madonna, G., Lopalco, P., & Silvestris, F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1387706 · Cited by 96
Schneider, S., Kadletz, L., Wiebringhaus, R., Kenner, L., Selzer, E., Füreder, T., Rajky, O., Berghoff, A. S., Preusser, M., & Heiduschka, G. (2018) · Histopathology · doi:10.1111/his.13646 · Cited by 95
Role of the microbiome in occurrence, development and treatment of pancreatic cancer
Wang, Y., Yang, G., You, L., Yang, J., Feng, M., Qiu, J., Zhao, F., Liu, Y., Cao, Z., Zheng, L., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1103-2 · Cited by 97
Labriola, M., Zhu, J., Gupta, R. T., McCall, S. J., Jackson, J., Kong, E., White, J. R., Cerqueira, G. C., Gerding, K., Simmons, J. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000319 · Cited by 97
Clear Cell Renal Cell Carcinoma: From Biology to Treatment
Kase, A. M., George, D. J., & Ramalingam, S. (2023) · Cancers · doi:10.3390/cancers15030665 · Cited by 98
Wu, J., Hong, D., Zhang, X., Lu, X., & Miao, J. (2017) · Scientific Reports · doi:10.1038/srep44173 · Cited by 96
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Carlo, M. I., Voss, M. H., & Motzer, R. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.103 · Cited by 95
Self-citationCurrent modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 96
Пили, Р., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorff, T. B., Olencki, T. E., Shen, L., Orillion, A. R., Lamonica, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1178 · Cited by 94
Self-citationGu, L., Khadaroo, P. A., Su, H., Kong, L., Chen, L., Wang, X., Li, X., Zhu, H., Zhong, X., Pan, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5785-z · Cited by 95
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung, V., Gupta, T., Olsson-Brown, A. C., Subramanian, S., Sasson, S. C., Heseltine, J., Fryer, E., Collantes, E., Sacco, J. J., Pirmohamed, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0882-y · Cited by 94
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Mollica, V., Rizzo, A., Montironi, R., Liang Cheng, C., Giunchi, F., Schiavina, R., Santoni, M., Fiorentino, M., Antonio Lopez-beltran, B., Brunocilla, E., et al. (2020) · Cancers · doi:10.3390/cancers12061449 · Cited by 94
Voss, M. H., Gordon, M. S., Mita, M. M., Rini, B. I., Makker, V., Macarulla, T. M., Smith, D. C., Cervantes, A. M. R., Puzanov, I. J., Пили, Р., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01041-x · Cited by 96
Sato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 100
Rajan, A., Kim, C., Heery, C. R., Guha, U., & Gulley, J. L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1175694 · Cited by 98
Molecular Imaging of Immunotherapy Targets in Cancer
Ehlerding, E. B., England, C. G., McNeel, D. G., & Cai, W. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177493 · Cited by 93
Maughan, B. L., Bailey, E. B., Gill, D. M., & Agarwal, N. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00056 · Cited by 93
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 95
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Porta, C., Cosmai, L., Leibovich, B. C., Powles, T. B., Gallieni, M. A., & Bex, A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0131-x · Cited by 93
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Tanegashima, T., Togashi, Y., Azuma, K., Kawahara, A., Ideguchi, K., Sugiyama, D., Kinoshita, F., Akiba, J., Kashiwagi, E., Takeuchi, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3991 · Cited by 93
Atkins, M. B., Jegede, O. A., Haas, N. B., McDermott, D. F., Bilen, M. A., Stein, M., Sosman, J. A., Alter, R., Plimack, E. R., Ornstein, M. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02938 · Cited by 93
Self-citationHuang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.005 · Cited by 94
Ahern, E. S., Harjunpää, H., O’Donnell, J. S., Allen, S. M., Dougall, W. C., Teng, M. W. L., & Smyth, M. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431088 · Cited by 93
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Inaguma, S., Lasota, J. P., Wang, Z., Felisiak-Gołąbek, A., Ikeda, H., & Miettinen, M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.185 · Cited by 93
Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade
Zha, H., Han, X., Zhu, Y. J., Yang, F., Li, Y., Li, Q., Guo, B., & Zhu, B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349587 · Cited by 92
Boilève, A., Carlo, M. I., Barthélémy, P., Oudard, S. M., Borchiellini, D., Voss, M. H., George, S., Chevreau, C., Landman‐Parker, J., Tabone, M.-D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0482-z · Cited by 93
Self-citationOnuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 95
Kas, B., Talbot, H., Ferrara, R., Richard, C., Lamarque, J.-P., Pitre-Champagnat, S., Planchard, D., Balleyguier, C., Besse, B., Mezquita, L., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1634 · Cited by 93
Shi, Y. X., Zhang, Q., Bi, H., Lu, M., Tan, Y., Zou, D., Ge, L., Chen, Z., Liu, C., Ci, W., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02651-9 · Cited by 94
Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death
Clucas, J., & Meier, P. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00623-w · Cited by 96
Rizzo, A., Mollica, V., Santoni, M., Ricci, A. D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., & Massari, F. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.03.001 · Cited by 91
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
Rieth, J. M., & Subramanian, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051340 · Cited by 92
Ishihara, H., Takagi, T., Kondo, T., Homma, C., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.03.003 · Cited by 91
Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 92
Chahoud, J., Msaouel, P., Campbell, M. T., Bathala, T. K., Xiao, L., Gao, J., Zurita, A. J., Shah, A. Y., Jonasch, E. W., Sharma, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0372 · Cited by 91
Self-citationCastello, A., Rossi, S., Mazziotti, E., Toschi, L., & Lopci, E. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237768 · Cited by 91
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Robatel, S., & Schenk, M. (2022) · Cancers · doi:10.3390/cancers14040985 · Cited by 94
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
McKenzie, J. A., Mbofung, R. M., Malu, S., Zhang, M., Ashkin, E. L., Devi, S., Williams, L. J., Tieu, T. N., Peng, W., Pradeep, S., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx257 · Cited by 91
Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
Gomes, J. R., Schmerling, R. A., Haddad, C. K., Racy, D. J., Ferrigno, R., Gil, E., Zanuncio, P. H. D. R., & Buzaid, A. C. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000141 · Cited by 90
Immunotherapy approaches in the treatment of malignant brain tumors
Dunn‐Pirio, A., & Vlahovic, G. (2016) · Cancer · doi:10.1002/cncr.30371 · Cited by 91
Colantuoni, E., Scharfstein, D. O., Wang, C., Hashem, M. D., Leroux, A., Needham, D. M., & Girard, T. D. (2018) · BMJ · doi:10.1136/bmj.j5748 · Cited by 90
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Matos, I. G., Martín-Liberal, J., García-Ruiz, A., Hierro, C., de Olza, M. O., Viaplana, C., Azaro, A., Vieito, M., Braña, I., Mur, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2226 · Cited by 92
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 94
Glioblastoma vaccines: past, present, and opportunities
Xiong, Z., Raphael, I., Olin, M. R., Okada, H., Li, X., & Kohanbash, G. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104963 · Cited by 97
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 101
Systemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Jin, Z., & Yoon, H. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.06 · Cited by 90
Sun, M., Marconi, L. S., Eisen, T. G., Escudier, B. J., Giles, R. H., Haas, N. B., Harshman, L. C., Quinn, D. I., Larkin, J., Pal, S. K., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.002 · Cited by 89
Self-citationImmune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 90
Leong, A., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228689 · Cited by 97
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Turgeon, G., Weickhardt, A. J., Azad, A., Solomon, B., & Siva, S. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12046 · Cited by 89
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
Medina, P. J., & Adams, V. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1714 · Cited by 90
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 88
Clinical Importance of Epstein–Barr Virus-Associated Gastric Cancer
Nishikawa, J., Iizasa, H., Yoshiyama, H., Shimokuri, K., Kobayashi, Y. O., Sasaki, S., Nakamura, M., Yanai, H., Sakai, K., Suehiro, Y., et al. (2018) · Cancers · doi:10.3390/cancers10060167 · Cited by 88
Lopez, A. T., & Geskin, L. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0128 · Cited by 88
Mutations in renal cell carcinoma
D’Avella, C. A., Abbosh, P. H., Pal, S. K., & Geynisman, D. M. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.027 · Cited by 89
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Perumal, D., Imai, N., Laganà, A., Finnigan, J. P., Melnekoff, D. T., Leshchenko, V. V., Solovyov, A., Madduri, D., Chari, A., Cho, H. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2309 · Cited by 92
Zhao, X., Shen, J., Ivaturi, V. D., Gopalakrishnan, M., Feng, Y., Schmidt, B. J., Statkevich, P., Goodman, V. L., Gobburu, J. V. S., Bello, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.015 · Cited by 88
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
